3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
3
Recruiting
1
Enrolling by invitation
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Myasthenia Gravis
1
Interventions
zilucoplan
1
rozanolixizumab
1
fludarabine phosphate
1
fludarabine
1
exemestane
1
epigallocatechin gallate
1
durvalumab
1
aumolertinib
1
atropine sulfate-diphenoxylate hydrochloride drug combination
1
Vincristine
1
Tamoxifen
1
Sodium Chloride
1
R-CHOP protocol
1
Prednisone
1
Pemetrexed
1
Omeprazole
1
Melphalan
1
Loperamide
1
Letrozole
1
High-Energy Shock Waves
1
Gastroscopy
1
Etoposide
1
Doxorubicin
1
Dexamethasone
1
Decitabine
1
Cytarabine
1
Cyclophosphamide
1
Cisplatin
1
Catechin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Enrolling by invitation
×
zilucoplan
×
Clear all
NCT06435312
2026-05-08
ziMyG+
UCB Pharma
Phase 3
Enrolling by invitation
8 enrolled